Abstract
The current literature covering cost-effectiveness and cost-utility analyses of biological treatments in patients with rheumatoid arthritis (RA) are reviewed in order to discuss options and limitations for future application of these highly priced drugs in routine clinical practice. The cost-effectiveness and cost-utility ratios of the studies analysed are converted into the corresponding Euros of the publication year. Etanercept treatment achieved a cost-effectiveness ratio of 44,300 Euros (2002)/ACR 20 (20% response according to American College of Rheumatology criteria) and 43,100 Euros (2002)/ACR 70WR (ACR 70 weighted response) compared with sulfasalazine and methotrexate, respectively, in methotrexate-naive RA. In methotrexate-resistant RA, the combination of etanercept and methotrexate is compared to a combination therapy of methotrexate, sulfasalazine and hydroxychloroquine revealing costs of 46,100 Euros (2000)/ACR 20, and 37,700 Euros/ACR 70WR. The cost-utility ratios for infliximab treatment range from 16,000 Euros to almost 166,000/QALY (quality adjusted life-year) gained, the studies investigating etanercept treatment show a ratio of approximately 25,000 Euros and 120,000/QALY gained. No substantial differences of c...Continue Reading
References
Jan 28, 1999·The New England Journal of Medicine·M E WeinblattD J Burge
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Jan 6, 2000·Lancet·R MainiP Lipsky
Oct 19, 2000·Arthritis and Rheumatism·H K ChoiK M Kuntz
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Dec 12, 2001·PharmacoEconomics·M J NuijtenM Koopmanschap
Apr 23, 2002·The Journal of Mental Health Policy and Economics·Donald S. Shepard
Apr 27, 2002·Zeitschrift für Rheumatologie·S MerkesdalH Zeidler
Oct 22, 2002·Health Technology Assessment : HTA·P JobanputraA Burls
Oct 29, 2002·The American Journal of Medicine·John B WongArthur Kavanaugh
Feb 22, 2003·Rheumatology·G KobeltK Eberhardt
Aug 2, 2003·Rheumatology·A BrennanP Conway
Dec 6, 2003·Rheumatology·S J BinghamP Emery
Dec 16, 2003·Annals of the Rheumatic Diseases·G KobeltP Geborek
Citations
Apr 11, 2006·Clinical & Developmental Immunology·Alan Ebringer, Taha Rashid
Jul 11, 2006·Der Radiologe·M TreitlS Wirth
Dec 23, 2006·Clinical Rheumatology·Taha Rashid, Alan Ebringer
Jan 9, 2007·Clinical Rheumatology·Taha Rashid, Alan Ebringer
Feb 15, 2005·Annals of the Rheumatic Diseases·G M ZimmermanM Maccarone Buonfigli
Oct 22, 2005·Annals of the Rheumatic Diseases·D E FurstP J Mease
Sep 4, 2014·Current Rheumatology Reports·Jonathan ToshRon Akehurst
Jan 13, 2012·Current Medical Research and Opinion·V F SchabertJ F Fries
Jan 7, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Eugénia NogueiraArtur Cavaco-Paulo
Nov 18, 2008·Journal of Clinical Epidemiology·Aimee Kendall RoundtreeMaria E Suarez-Almazor
Jul 29, 2006·Arthritis and Rheumatism·Michael C Y TanCarlo A Marra
Sep 28, 2007·Anesthesia and Analgesia·Michael BernateckMatthias Karst
Jan 16, 2010·International Journal of Immunopathology and Pharmacology·M BenucciM Manfredi